ClinicalTrials.gg
CompletedNCT02631837HALONUpdated Apr 11, 2023Results posted

Hysterectomy by Transabdominal Laparoscopy or NOTES

An interventional study of vNOTES hysterectomy and LSC hysterectomy in Uterine Diseases, sponsored by Imelda Hospital, Bonheiden. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-11.

Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

Objective: To randomly compare hysterectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) versus laparoscopy uterus in women with benign gynecological pathology.

Study design: Randomized controlled/single center/single-blinded/parallel-group/non-inferiority/efficacy trial.

Study population: All women aged 18 to 70 years regardless of parity with a non-prolapsed uterus and a benign indication for hysterectomy.

Primary study outcome parameters: successful removal of the uterus by the intended technique.

Secondary outcomes: the proportion of women admitted to the in-hospital ward; postoperative pain scores; the total amount of analgesics used; postoperative infection; per- or postoperative complications; hospital readmission rates; duration of the surgical procedure; incidence and intensity of dyspareunia; sexual wellbeing; health-related quality of life; costs.

Read the detailed description

l1.Objectives of the HALON Trial The primary research questions of this IDEAL stage 2b efficacy trial are as follows: is a vNOTES (vaginal Natural Orifice Transluminal Endoscopic Surgery) hysterectomy at least as effective compared to the standard transabdominal laparoscopic approach (LSC) for removing a non-prolapsed uterus without the need for conversion to an alternative approach? (non inferiority design)

Secondary research questions are:

  • Do more women treated by vNOTES prefer to leave the day care unit on the day of surgery compared to LSC?
  • Do women treated by vNOTES suffer from less pain compared to women treated by LSC in the first postoperative week?
  • Is the removal of a uterus by vNOTES faster compared to LSC?
  • Does a vNOTES cause more pelvic infection or other complications compared to LSC?
  • Does a vNOTES result in more hospital readmissions within 6 weeks after surgery compared to LSC?
  • Does a vNOTES approach result in more women reporting dyspareunia, less sexual wellbeing or less health-related quality of life at 3 or 6 months after surgery when compared to women treated by LSC?
  • What are the direct and indirect costs up to 6 weeks after the surgical intervention of a vNOTES compared to LSC? 2. TRIAL DESIGN 2.1. Design A single center, single-blinded, parallel group randomized, non-inferiority efficacy trial.

2.2. Simple pilot randomized trial. 2.3. Time schedule Based upon the mean number of hysterectomies performed annually for benign gynecological disease at the department of Obstetrics and Gynecology of the participating center (168) the investigators estimate that the duration of recruitment will be 12 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2 years.

2.4. Participating center Department of Obstetrics and Gynecology Imeldahospital Imeldalaan 9 2820 Bonheiden Belgium 3. ELIGIBILITY, CONSENT AND RANDOMIZATION 3.1. Screening and consent prior to surgery All women aged 18 to 70 years, regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication are eligible for inclusion.

3.2. Determining eligibility All women aged 18 to 70 years, regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication who provide consent to participation are eligible in the HALON trial and will be randomized before the procedure.

3.3. Randomization If the woman is eligible for the HALON trial, the trial secretary will obtain a randomized allocation the day before surgery. This will be done using a randomization list generated by a free computer software program offered by Research Randomizer (https://www.randomizer.org). The random sequence generation will be concealed using sequentially numbered opaque sealed envelopes. The envelope will be opened by the nurse assistant the day before surgery for practical logistic reasons.

3.4. Patients with strong preference for treatment A minority of women will express a clear preference for one of both treatments (e.g. strong desire to have no scar) and for this reason will not wish to be randomized between surgical treatments. To investigate how outcomes vary by choice, these women could be followed up in exactly the same way as for those women randomized into the HALON trial. A formal non-randomized follow-up of these women will not be done for logistical reasons.

3.5. Stratification of randomization A blocked randomization procedure will be used to avoid chance imbalances for the parameter 'uterine size'.

  1. TREATMENT ALLOCATIONS 4.1. Surgical procedures The principal investigator, who has training and experience in both laparoscopy and NOTES, will perform all surgical procedures. He is therefore not blinded. All vNOTES participants will be blinded by three superficial non-therapeutic or "mock" skin incisions similar to those done with the laparoscopic technique.

4.1.1 vNOTES hysterectomy This is the surgical procedure done in the intervention arm of the HALON trial. 4.1.2 LSC hysterectomy This is the surgical procedure done in the control arm of the HALON trial. 5. FOLLOW-UP AND OUTCOME MEASURES 5.1. Clinical assessments 5.1.1 Format PROMs (Patient reported outcomes) will be collected using a postal questionnaire, which will include a combination of disease specific (Pain on sexual intercourse measured by VAS scale and SSFS Scale) and generic measurement instruments (EQ-5D).

The postal questionnaires will be sent from the HALON Trial Office with postage paid envelopes two weeks before the due date. Reminders will be sent to patients if the questionnaire is not returned within one week of the due date and attempts will be made to contact the patient by phone if the questionnaire is not returned by two weeks after the due date.

5.1.2 Timing of assessments The primary outcome will be measured clinically at the end of the surgical procedure. In addition PROMs will take place at baseline (pain on sexual intercourse, health-related quality of life and sexual well being), the evening of the surgical intervention (in-hospital admission), during the first postoperative week (pain by VAS scores and analgetic drugs) and at 3 and 6 months (dyspareunia/ sexual well being/health related quality of life). Clinical physician assessment will take place the evening of the surgical intervention (in-hospital admission) and during the first six weeks following surgery (pelvic infection, surgical complications, hospital readmission rate).

5.2. Primary clinical outcome measure The proportion of women successfully treated by removing the uterus by the intended approach without conversion to another approach, using a dichotomous outcome measure, will be used as a measure of efficacy.

5.3. Secondary clinical outcome measures

The following secondary outcomes will be measured:

  • The proportion of women addmitted in-hospital for at least one night observation based on their own preference, as a dichotomous outcome.
  • Postoperative pain scores, as an ordinal outcome, measured using a Visual Analogue Scale (VAS) twice daily from day 1 till 7 self-reported by the participating women. The VAS scores range from 0= no pain to 10= worst imaginable pain.
  • Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.
  • Postoperative infection as a dichotomous outcome.
  • Per- or postoperative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome.
  • The number of women readmitted to hospital within 6 weeks following surgery.
  • Incidence and intensity of dyspareunia recorded by the participants at baseline, 3 and 6 months by self-reporting using a simple questionnaire and a Visual Analogue Scale (VAS) scale, as a dichotomous and ordinal outcome. The VAS scores range from 0= no pain to 10= worst imaginable pain.
  • Sexual wellbeing at baseline, at 3 and 6 months by self-reporting the Short Sexual Functioning Scale (SSFS). The SSFS is a questionnaire with 7 multiple choice open ended questions.
  • Health related quality of life, at baseline, at 3 and 6 months by self-reporting the EQ-5D-3L scale. The EQ-5D-3L scale is a questionnaire on 5 domains with 3 open ended questions and a scale from 0= worst possible health-related quality of life to 100= best possible health-related quality of life.
  • Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/abdominal wound closure, as a continuous outcome. 5.4.The direct and indirect costs up to 6 weeks after the hysterectomy of the vNOTES technique compared to LSC.

    1. ACCRUAL AND ANALYSIS 6.1. Sample size The sample size for the primary outcome of this trial has been chosen to give good statistical power to preclude any clinically important inferiority of vNOTES compared to laparoscopy and is based on evidence retrieved from a Dutch prospective cohort study. Based on the power calculations for the primary outcome and assuming a loss-to-follow-up rate of 15% we decided to include 66 study participants in the HALON trial.

6.2. Projected accrual and attrition rates Based upon the mean number of hysterectomies performed annually at the department of Obstetrics and Gynecology of the participating center (168) the investigators anticipate that the duration of recruitment will be 12 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2 years. First publication will be possible within four years of trial commencement.

The sample size calculations have allowed for a 15% loss to follow up rate. In order to minimize rates of attrition a dedicated research secretary will be employed to optimize recruitment and follow up.

02

Conditions studied

  • Uterine Diseases

Browse trials for

Keywords

  • NOTES
  • Laparoscopic surgery
03

In context

Uterine Diseases

73 studies on the registry are indexed under Uterine Diseases; 9 are open to participants now.

This study's enrollment of 70 is below the median of 80 across 58 interventional studies indexed under Uterine Diseases.

Browse Uterine Diseases studies →

Lead sponsor

Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All women aged 18 to 70 years regardless of parity, with a non-prolapsed uterus in need of a hysterectomy for benign indication
  • Written obtained prior to surgery

Exclusion criteria

Exclusion Criteria:

  • History of rectal surgery
  • Suspected rectovaginal endometriosis
  • Suspected
  • History of pelvic inflammatory disease, especially prior tubo-ovarian or pouch of Douglas abscess
  • Active lower genital tract infection e.g. Chlamydia, N. gonorrhoeae
  • Virgo
  • Pregnancy
  • Failure to provide written prior to surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    vNOTES hysterectomy

    vaginal Natural Orifice Transluminal Endoscopic Surgery

    Procedure: vNOTES hysterectomy

  • Active comparator
    LSC hysterectomy

    Laparoscopic hysterectomy

    Procedure: LSC hysterectomy

Interventions

  • ProcedurevNOTES hysterectomy

    Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy

  • ProcedureLSC hysterectomy

    Surgical removal of the uterus by transabdominal laparoscopy

06

What researchers measure

Primary outcomes

  1. Successful Removal of the Uterus Without Conversion to Another Technique

    Successful removal of the uterus without conversion to another technique with or without morcellation

    Time frame: Intraoperative

Secondary outcomes

  1. Admission in Hospital for at Least One Night Observation

    The number of women admitted in-hospital for at least one night observation based on their own preference after discharge from the day care unit, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight.

    Time frame: Measured on the day of the surgical intervention

  2. Postoperative Pain Scores

    Postoperative pain scores, as an ordinal outcome, measured using a Visual Analogue Scale (VAS) twice daily (morning and evening) from day 1 till 7 selfreported by the participating women. VAS scores from 0 to 10 with 0 = no pain and 10= worst pain ever imaginable.

    Time frame: The first seven days after the surgical intervention

  3. The Use of Analgetic Drugs for Postoperative Pain

    Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.

    Time frame: The first week after the surgical intervention

  4. Postoperative Infection

    Postoperative infection defined by lower abdominal pain with fever \> 38°C and positive clinical signs or laboratory findings, detected during the first six weeks of surgery, as a dichotomous outcome.

    Time frame: The first six weeks after the surgical intervention

  5. Intra- Operative Complications

    Intra- operative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome

    Time frame: At the time of the surgical intervention

  6. Postoperative Complications

    Postoperative complications detected during the first six weeks of surgery, as a dichotomous outcome

    Time frame: The first six weeks after the surgical intervention

  7. Hospital Readmission

    The number of women readmitted to hospital within six weeks following surgery, as a dichotomous outcome.

    Time frame: The first six weeks after the surgical intervention

  8. Duration of the Surgical Intervention

    Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/ abdominal wound closure, as a continuous outcome

    Time frame: Intraoperative

  9. Vaginal Pain During Sexual Intercourse at Three Months

    Incidence of vaginal dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.

    Time frame: At 3 months after the surgical intervention

  10. Vaginal Pain During Sexual Intercourse at Six Months

    Incidence of vaginal dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire

    Time frame: At 6 months after the surgical intervention

  11. Pelvic Pain During Sexual Intercourse at Three Months

    Incidence of pelvic dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.

    Time frame: At 3 months after the surgical intervention

  12. Pelvic Pain During Sexual Intercourse at Six Months

    Incidence of pelvic dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire.

    Time frame: At 6 months after the surgical intervention

  13. Health-related Quality of Life at Three Months

    Health-related quality of life at 3 months by self-reporting the EQ-5D scale.The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).

    Time frame: At 3 months after the surgical intervention

  14. Health-related Quality of Life at Six Months

    Health-related quality of life at 6 months by self-reporting the EQ-5D scale. The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).

    Time frame: At 6 months after the surgical intervention

  15. Sexual Well Being

    Sexual wellbeing at baseline, at 3 and 6 months by self-reporting using the SSFS (Short Sexual Function Scale). The SSFS is a questionnaire of 7 open ended questions on sexual wellbeing.

    Time frame: At baseline, 3 months and 6 months after the surgical intervention

  16. Direct Costs

    Calculating the comparative direct costs in USD of both techniques up to 6 weeks after the surgical intervention

    Time frame: Up to 6 weeks postoperative

07

Results

Posted Jun 11, 2020
Limitations and caveats
Data on sexual well-being will be analysed at a later date. We received the 6 month study questionnaire of the last recruited participant A53 on 15-07-2017. We noted this date as the actual study completion date in the trial register. Although the secondary outcomes at 6 months of this last patient were received one month earlier due to the very timely sending of the questionnaire by our study secretary we decided to consider them as valid, since only secondary outcomes were collected.

Participant flow

Between December 9, 2015, and February 23, 2017, 194 women were screened for eligibility

Participant flow — Overall Study
MilestonevNOTES HysterectomyLSC Hysterectomy
Started3535
Completed3535
Not completed00

Outcome measures

PrimarySuccessful Removal of the Uterus Without Conversion to Another Technique

Successful removal of the uterus without conversion to another technique with or without morcellation

Time frame:
Intraoperative
Reported as:
Count of participants · Participants
Successful Removal of the Uterus Without Conversion to Another Technique
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Successful Removal of the Uterus Without Conversion to Another Technique3535
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Farrington-Manning · p = 0.0221 (The Farrington-Manning test for non-inferiority was performed with 5% significance level and yielded P = 0.0221 in a sensitivity analysis assuming one conversion in the vNOTES and 0 conversions in the laparoscopy group.)
SecondaryAdmission in Hospital for at Least One Night Observation

The number of women admitted in-hospital for at least one night observation based on their own preference after discharge from the day care unit, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight.

Time frame:
Measured on the day of the surgical intervention
Reported as:
Count of participants · Participants
Admission in Hospital for at Least One Night Observation
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Admission in Hospital for at Least One Night Observation820
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Fisher Exact · p = 0.007 · Risk difference (rd): -0.34 · 95% CI -0.56 to -0.13
  • vNOTES Hysterectomy vs LSC Hysterectomy · Fisher Exact · p = 0.007
SecondaryPostoperative Pain Scores

Postoperative pain scores, as an ordinal outcome, measured using a Visual Analogue Scale (VAS) twice daily (morning and evening) from day 1 till 7 selfreported by the participating women. VAS scores from 0 to 10 with 0 = no pain and 10= worst pain ever imaginable.

Time frame:
The first seven days after the surgical intervention
Reported as:
Mean · units on a scale
Postoperative Pain Scores
units on a scalevNOTES HysterectomyLSC Hysterectomy
mean pain VAS score day 1 morning3.629 (2.877 to 4.380)4.200 (3.449 to 4.951)
mean pain VAS score day 1 evening3.486 (2.815 to 4.157)4.456 (3.783 to 5.129)
mean pain VAS score day 2 morning2.486 (1.876 to 3.096)3.543 (2.933 to 4.153)
mean pain VAS score day 2 evening2.514 (1.947 to 3.082)3.343 (2.775 to 3.910)
mean pain VAS score day 3 morning1.800 (1.261 to 2.339)2.800 (2.261 to 3.339)
mean pain VAS score day 3 evening1.857 (1.335 to 2.379)2.914 (2.392 to 3.436)
mean pain VAS score day 4 morning1.257 (0.746 to 1.769)2.286 (1.774 to 2.797)
mean pain VAS score day 4 evening1.371 (0.867 to 1.876)2.457 (1.952 to 2.962)
mean pain VAS score day 5 morning1.143 (0.643 to 1.642)1.914 (1.415 to 2.414)
mean pain VAS score day 5 evening1.057 (0.562 to 1.553)2.086 (1.590 to 2.581)
mean pain VAS score day 6 morning0.914 (0.421 to 1.407)1.914 (1.421 to 2.407)
mean pain VAS score day 6 evening1.086 (0.591 to 1.580)2.000 (1.505 to 2.495)
mean pain VAS score day 7 morning1.029 (0.525 to 1.532)1.567 (1.060 to 2.074)
mean pain VAS score day 7 evening0.819 (0.290 to 1.348)1.693 (1.153 to 2.233)
SecondaryThe Use of Analgetic Drugs for Postoperative Pain

Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.

Time frame:
The first week after the surgical intervention
Reported as:
Mean · number of tablets
The Use of Analgetic Drugs for Postoperative Pain
number of tabletsvNOTES HysterectomyLSC Hysterectomy
The Use of Analgetic Drugs for Postoperative Pain8.0 (0 to 28)13.9 (0 to 50)
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Mann-Whitney U test · p = 0.006 · Mean difference (final values): -5.9 · 95% CI -10 to -1.8Two-sided test
SecondaryPostoperative Infection

Postoperative infection defined by lower abdominal pain with fever \> 38°C and positive clinical signs or laboratory findings, detected during the first six weeks of surgery, as a dichotomous outcome.

Time frame:
The first six weeks after the surgical intervention
Reported as:
Count of participants · Participants
Postoperative Infection
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Postoperative Infection12
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Fisher Exact · p = 1.00
SecondaryIntra- Operative Complications

Intra- operative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome

Time frame:
At the time of the surgical intervention
Reported as:
Count of participants · Participants
Intra- Operative Complications
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Intra- Operative Complications10
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Fisher Exact · p = > 0.05
SecondaryPostoperative Complications

Postoperative complications detected during the first six weeks of surgery, as a dichotomous outcome

Time frame:
The first six weeks after the surgical intervention
Reported as:
Count of participants · Participants
Postoperative Complications
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Postoperative Complications313
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Fisher Exact · p = 0.009 · Risk difference (rd): -0.29 · 95% CI -0.47 to -0.10
SecondaryHospital Readmission

The number of women readmitted to hospital within six weeks following surgery, as a dichotomous outcome.

Time frame:
The first six weeks after the surgical intervention
Reported as:
Count of participants · Participants
Hospital Readmission
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Hospital Readmission16
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Fisher Exact · p = 0.106
SecondaryDuration of the Surgical Intervention

Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/ abdominal wound closure, as a continuous outcome

Time frame:
Intraoperative
Reported as:
Mean · minutes
Duration of the Surgical Intervention
minutesvNOTES HysterectomyLSC Hysterectomy
Duration of the Surgical Intervention41.1 (21.0 to 130.0)75.1 (40.0 to 189.0)
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Mann-Whitney U test · p = < 0.01 · Median difference (final values): -34 · 95% CI -46 to -22
SecondaryVaginal Pain During Sexual Intercourse at Three Months

Incidence of vaginal dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.

Time frame:
At 3 months after the surgical intervention
Reported as:
Count of participants · Participants
Vaginal Pain During Sexual Intercourse at Three Months
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Vaginal Pain During Sexual Intercourse at Three Months89
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Arm by time interaction · p = 0.7604 (We tested a treatment arm by time interaction to study changes in differences for the outcomes during the follow-up period. In absence of such an interaction (p\>0.05 for the interaction term), the main effect of treatment was tested.)
SecondaryVaginal Pain During Sexual Intercourse at Six Months

Incidence of vaginal dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire

Time frame:
At 6 months after the surgical intervention
Reported as:
Count of participants · Participants
Vaginal Pain During Sexual Intercourse at Six Months
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Vaginal Pain During Sexual Intercourse at Six Months58
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Arm by time interaction · p = 0.3071 (We tested a treatment arm by time interaction to study changes in differences for the outcomes during the follow-up period. In absence of such an interaction (p\>0.05 for the interaction term), the main effect of treatment was tested.)
SecondaryPelvic Pain During Sexual Intercourse at Three Months

Incidence of pelvic dyspareunia recorded by the participants at 3 months by self-reporting using a simple questionnaire.

Time frame:
At 3 months after the surgical intervention
Reported as:
Count of participants · Participants
Pelvic Pain During Sexual Intercourse at Three Months
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Pelvic Pain During Sexual Intercourse at Three Months68
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Arm by time interaction · p = 0.4541 (We tested a treatment arm by time interaction to study changes in differences for the outcomes during the follow-up period. In absence of such an interaction (p\>0.05 for the interaction term), the main effect of treatment was tested.)
SecondaryPelvic Pain During Sexual Intercourse at Six Months

Incidence of pelvic dyspareunia recorded by the participants at 6 months by self-reporting using a simple questionnaire.

Time frame:
At 6 months after the surgical intervention
Reported as:
Count of participants · Participants
Pelvic Pain During Sexual Intercourse at Six Months
ParticipantsvNOTES HysterectomyLSC Hysterectomy
Pelvic Pain During Sexual Intercourse at Six Months45
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Arm by time interaction · p = 0.4514 (We tested a treatment arm by time interaction to study changes in differences for the outcomes during the follow-up period. In absence of such an interaction (p\>0.05 for the interaction term), the main effect of treatment was tested.)
SecondaryHealth-related Quality of Life at Three Months

Health-related quality of life at 3 months by self-reporting the EQ-5D scale.The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).

Time frame:
At 3 months after the surgical intervention
Reported as:
Mean · score on a scale
Health-related Quality of Life at Three Months
score on a scalevNOTES HysterectomyLSC Hysterectomy
Health-related Quality of Life at Three Months83.8 (40.0 to 100.0)79.6 (20.0 to 100.0)
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Arm by time interaction · p = 0.3473 (We tested a treatment arm by time interaction to study changes in differences for the outcomes during the follow-up period. In absence of such an interaction (p\>0.05 for the interaction term), the main effect of treatment was tested.)
SecondaryHealth-related Quality of Life at Six Months

Health-related quality of life at 6 months by self-reporting the EQ-5D scale. The reported values for the health-related quality of life are self-reported values using the VAS part of the two part EQ-5D-3L questionnaire. The scale ranges from 0 (worst quality) to 100 (best quality).

Time frame:
At 6 months after the surgical intervention
Reported as:
Mean · score on a scale
Health-related Quality of Life at Six Months
score on a scalevNOTES HysterectomyLSC Hysterectomy
Health-related Quality of Life at Six Months87.8 (60.0 to 100.0)86.6 (65.0 to 100.0)
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Arm by time interaction · p = 0.3473 (We tested a treatment arm by time interaction to study changes in differences for the outcomes during the follow-up period. In absence of such an interaction (p\>0.05 for the interaction term), the main effect of treatment was tested.)
SecondarySexual Well Being

Sexual wellbeing at baseline, at 3 and 6 months by self-reporting using the SSFS (Short Sexual Function Scale). The SSFS is a questionnaire of 7 open ended questions on sexual wellbeing.

Time frame:
At baseline, 3 months and 6 months after the surgical intervention

Results for this outcome have not been posted.

SecondaryDirect Costs

Calculating the comparative direct costs in USD of both techniques up to 6 weeks after the surgical intervention

Time frame:
Up to 6 weeks postoperative
Reported as:
Mean · USD
Direct Costs
USDvNOTES HysterectomyLSC Hysterectomy
Direct Costs3452.2 (2404.6 to 4897.1)3933.6 (2120.6 to 6776.2)
Statistical analysis
  • vNOTES Hysterectomy vs LSC Hysterectomy · Mann-Whitney U test · p = 0.110 · Mean difference (final values): -555.8 · 95% CI -1,044 to 36

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
vNOTES Hysterectomy0/35 (0%)0/35 (0%)3/35 (8.6%)
LSC Hysterectomy0/35 (0%)2/35 (5.7%)11/35 (31.4%)
Most frequent serious events
Most frequent serious events
EventvNOTES HysterectomyLSC Hysterectomy
vesicovaginal fistulaRenal and urinary disorders0/351/35
Pulmonary embolusRespiratory, thoracic and mediastinal disorders0/351/35
Most frequent other events
Most frequent other events
EventvNOTES HysterectomyLSC Hysterectomy
Urinary tract infectionRenal and urinary disorders2/359/35
Blood transfusionBlood and lymphatic system disorders1/352/35

Baseline characteristics

All participants included were women.

Age, Continuous
Age, Continuous(Years)vNOTES HysterectomyLSC HysterectomyTotal
Mean46 (24 to 65)49 (34 to 68)47 (24 to 68)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)vNOTES HysterectomyLSC HysterectomyTotal
Female353570
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)vNOTES HysterectomyLSC HysterectomyTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)vNOTES HysterectomyLSC HysterectomyTotal
Belgium353570
Body Mass Index
Body Mass Index(kg/m²)vNOTES HysterectomyLSC HysterectomyTotal
Mean26.6 (17.7 to 44.1)26.4 (18.6 to 42.9)26.5 (17.7 to 44.1)
Number of vaginal births
Number of vaginal births(number of vaginal births)vNOTES HysterectomyLSC HysterectomyTotal
Mean1.4 (0 to 4)1.3 (0 to 3)1.4 (0 to 4)
Prior abdominal surgery
Prior abdominal surgery(Participants)vNOTES HysterectomyLSC HysterectomyTotal
Count of participants201636
Prior Caesarean section
Prior Caesarean section(Participants)vNOTES HysterectomyLSC HysterectomyTotal
Count of participants8513

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Imelda Hospital
    Bonheiden, Antwerp 2820, Belgium
09

References and documents

Publications

  • Reynders A, Baekelandt J. Adnexectomy by Poor Man's Transvaginal NOTES. Gynecol Surg 2015; 12: 207-11
  • Van Peer S, Baekelandt J. Natural orifice transluminal endoscopic surgery (NOTES) salpingectomy for ectopic pregnancy: a first series demonstrating how a new surgical technique can be applied in a low-resource setting. Gynecol Surg 2015; 12: 299-302
  • Baekelandt J, De Mulder PA, Le Roy I, Mathieu C, Laenen A, Enzlin P, Weyers S, Mol BW, Bosteels JJ. HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery: a randomised controlled trial (study protocol). BMJ Open. 2016 Aug 12;6(8):e011546. doi: 10.1136/bmjopen-2016-011546. PubMed 27519922 ↗
  • Baekelandt JF, De Mulder PA, Le Roy I, Mathieu C, Laenen A, Enzlin P, Weyers S, Mol B, Bosteels J. Hysterectomy by transvaginal natural orifice transluminal endoscopic surgery versus laparoscopy as a day-care procedure: a randomised controlled trial. BJOG. 2019 Jan;126(1):105-113. doi: 10.1111/1471-0528.15504. PubMed 30325565 ↗
  • Su H, Yen CF, Wu KY, Han CM, Lee CL. Hysterectomy via transvaginal natural orifice transluminal endoscopic surgery (NOTES): feasibility of an innovative approach. Taiwan J Obstet Gynecol. 2012 Jun;51(2):217-21. doi: 10.1016/j.tjog.2012.04.009. PubMed 22795097 ↗
  • Lee CL, Wu KY, Su H, Wu PJ, Han CM, Yen CF. Hysterectomy by transvaginal natural orifice transluminal endoscopic surgery (NOTES): a series of 137 patients. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):818-24. doi: 10.1016/j.jmig.2014.03.011. Epub 2014 Mar 25. PubMed 24681063 ↗
  • Atallah S, Martin-Perez B, Albert M, Schoonyoung H, Quinteros F, Hunter L, Larach S. Vaginal Access Minimally Invasive Surgery (VAMIS): A New Approach to Hysterectomy. Surg Innov. 2015 Aug;22(4):344-7. doi: 10.1177/1553350614560273. Epub 2014 Nov 27. PubMed 25432882 ↗
  • Yang YS, Kim SY, Hur MH, Oh KY. Natural orifice transluminal endoscopic surgery-assisted versus single-port laparoscopic-assisted vaginal hysterectomy: a case-matched study. J Minim Invasive Gynecol. 2014 Jul-Aug;21(4):624-31. doi: 10.1016/j.jmig.2014.01.005. Epub 2014 Jan 21. PubMed 24462594 ↗
  • Wang CJ, Huang HY, Huang CY, Su H. Hysterectomy via transvaginal natural orifice transluminal endoscopic surgery for nonprolapsed uteri. Surg Endosc. 2015 Jan;29(1):100-7. doi: 10.1007/s00464-014-3639-y. Epub 2014 Oct 1. PubMed 25270610 ↗
  • Baekelandt J. Total Vaginal NOTES Hysterectomy: A New Approach to Hysterectomy. J Minim Invasive Gynecol. 2015 Sep-Oct;22(6):1088-94. doi: 10.1016/j.jmig.2015.05.015. Epub 2015 May 22. PubMed 26009278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Feb 2017, 14 months.

Results were first posted in Jun 2020, 3 years 3 months after primary completion.

Of 28 interventional studies with no phase under Uterine Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2015
First posted
Dec 16, 2015
StartActual
Dec 2015
Primary completionActual
Feb 24, 2017
CompletionActual
Jul 15, 2017
Results first posted
Jun 11, 2020
Last update
Apr 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02631837
Lead sponsor
Imelda Hospital, Bonheiden
Responsible party
Dr Jan Baekelandt, MD (Dr, Imelda Hospital, Bonheiden) — Principal investigator
First posted
Dec 16, 2015
Start date
Dec 2015
Primary completion
Feb 24, 2017
Completion
Jul 15, 2017
Results posted
Jun 11, 2020
Last update
Apr 11, 2023

Study contacts

Jan Baekelandt, MD
principal investigator · Imelda Hospital, Bonheiden

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion